Last reviewed · How we verify

Head And Neck Cancer — Treatment Landscape & Competitive Intelligence

Head And Neck Cancer (Oncology) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Oncology 3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Head And Neck Cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Opdivo nivolumab Bristol-Myers Squibb Programmed Death Receptor-1 Blocking Antibody [EPC] Programmed cell death protein 1 2014-01-01
Erbitux cetuximab Imclone Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor 2004-01-01
Erbitux Erbitux Hellenic Oncology Research Group Epidermal growth factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 1 drug in Head And Neck Cancer
  2. Hellenic Oncology Research Group · 1 drug in Head And Neck Cancer
  3. Imclone · 1 drug in Head And Neck Cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Head And Neck Cancer:

Cite this brief

Drug Landscape (2026). Head And Neck Cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/head-and-neck-cancer. Accessed 2026-05-16.

Related